Cátia Cunha1, Suceena Alexander2, Damien Ashby3, Janet Lee4, Gary Chusney4, Tom D Cairns3, Liz Lightstone3,5. 1. Nephrology Department, Centro Hospitalar de VilaNova de Gaia/Espinho, Vila Nova de Gaia, Portugal. 2. Nephrology Department, Christian Medical College Vellore, Vellore, Tamilnadu, India. 3. Imperial College Lupus Centre, Imperial College Healthcare NHS Trust, London, UK. 4. Leslie Brent Laboratory, Imperial College Healthcare NHS Trust, London, UK. 5. Section of Renal Medicine, Department of Medicine, Imperial College London, UK.
Abstract
Background: Hydroxychloroquine (HCQ) is a recommended drug in systemic lupus erythematosus (SLE). It has a long terminal half-life, making it an attractive target for therapeutic drug monitoring. The aim of this study was to establish a relationship between blood HCQ concentration and lupus nephritis activity. Methods: We conducted a retrospective observational study with data collected from clinical and laboratory records. Inclusion criteria were patients followed in the lupus clinic with biopsy-proven International Society of Nephrology/Renal Pathology Society Classes III, IV or V lupus nephritis on HCQ for at least 3 months (200-400 mg daily) and with HCQ levels measured during treatment. Exclusion criteria were patients on renal replacement therapy at baseline or patients lost to follow-up. Results: In 171 patients, the HCQ level was measured in 1282 samples. The mean HCQ blood level was 0.75±0.54mg/L and it was bimodally distributed. An HCQ level <0.20 mg/L [232 samples (18.1%)] appeared to define a distinct group of abnormally low HCQ levels. For patients in complete or partial remission at baseline compared with those remaining in remission, patients with renal flare during follow-up had a significantly lower average HCQ level (0.59 versus 0.81 mg/L; P= 0.005). Our data suggest an HCQ target level to reduce the likelihood of renal flares >0.6 mg/L (600 ng/mL) in those patients with lupus nephritis. Conclusion: HCQ level monitoring may offer a new approach to identify non-adherent patients and support them appropriately. We propose an HCQ minimum target level of at least 0.6 mg/L to reduce the renal flare rate, but this will require a prospective study for validation.
Background: Hydroxychloroquine (HCQ) is a recommended drug in systemic lupus erythematosus (SLE). It has a long terminal half-life, making it an attractive target for therapeutic drug monitoring. The aim of this study was to establish a relationship between blood HCQ concentration and lupus nephritis activity. Methods: We conducted a retrospective observational study with data collected from clinical and laboratory records. Inclusion criteria were patients followed in the lupus clinic with biopsy-proven International Society of Nephrology/Renal Pathology Society Classes III, IV or V lupus nephritis on HCQ for at least 3 months (200-400 mg daily) and with HCQ levels measured during treatment. Exclusion criteria were patients on renal replacement therapy at baseline or patients lost to follow-up. Results: In 171 patients, the HCQ level was measured in 1282 samples. The mean HCQ blood level was 0.75±0.54mg/L and it was bimodally distributed. An HCQ level <0.20 mg/L [232 samples (18.1%)] appeared to define a distinct group of abnormally low HCQ levels. For patients in complete or partial remission at baseline compared with those remaining in remission, patients with renal flare during follow-up had a significantly lower average HCQ level (0.59 versus 0.81 mg/L; P= 0.005). Our data suggest an HCQ target level to reduce the likelihood of renal flares >0.6 mg/L (600 ng/mL) in those patients with lupus nephritis. Conclusion: HCQ level monitoring may offer a new approach to identify non-adherent patients and support them appropriately. We propose an HCQ minimum target level of at least 0.6 mg/L to reduce the renal flare rate, but this will require a prospective study for validation.
Authors: Maria Dall'Era; David Stone; Victoria Levesque; Miriam Cisternas; David Wofsy Journal: Arthritis Care Res (Hoboken) Date: 2010-11-15 Impact factor: 4.794
Authors: M Jallouli; L Galicier; N Zahr; O Aumaître; C Francès; V Le Guern; F Lioté; A Smail; N Limal; L Perard; H Desmurs-Clavel; D Le Thi Huong; B Asli; J-E Kahn; J Pourrat; L Sailler; F Ackermann; T Papo; K Sacré; O Fain; J Stirnemann; P Cacoub; G Leroux; J Cohen-Bittan; J Sellam; X Mariette; B Blanchet; J S Hulot; Z Amoura; J C Piette; N Costedoat-Chalumeau Journal: Arthritis Rheumatol Date: 2015-05 Impact factor: 10.995
Authors: Guillermo J Pons-Estel; Graciela S Alarcón; Gerald McGwin; Maria I Danila; Jie Zhang; Holly M Bastian; John D Reveille; Luis M Vilá Journal: Arthritis Rheum Date: 2009-06-15
Authors: Farah Tamirou; Bernard R Lauwerys; Maria Dall'Era; Meggan Mackay; Brad Rovin; Ricard Cervera; Frédéric A Houssiau Journal: Lupus Sci Med Date: 2015-11-12